U.S. Patent Office Awards Diffusion Exclusive Rights for Use of TSC in Conjunction with Only FDA-Approved Stroke Therapeutic
December 17, 2018 09:55 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan
December 13, 2018 14:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals Chief Scientific Officer Dr. John L. Gainer to Present at 2018 Annual Meeting of the Society for NeuroOncology
November 15, 2018 09:15 ET
|
Diffusion Pharmaceuticals Inc.
Poster Presentation to Focus on Phase 3 GBM Brain Cancer Clinical Trial; 40 Percent Survival Rate for Biopsy-only Patients in Phase 2 Represents Fourfold Increase Above Historical Average For Those...
Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 14, 2018 09:00 ET
|
Diffusion Pharmaceuticals Inc.
Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NEWSWIRE) --...
Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum
October 15, 2018 12:00 ET
|
Diffusion Pharmaceuticals Inc.
Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment CHARLOTTESVILLE, Va., Oct. 15,...
Diffusion Names William (“Bill”) Hornung Chief Financial Officer
September 25, 2018 09:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals
September 12, 2018 09:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
Diffusion Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 29, 2018 08:00 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving...
Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
August 13, 2018 08:30 ET
|
Diffusion Pharmaceuticals Inc.
Enrollment continues in Phase 3 GBM brain cancer trialKey European patent validated covering oral formulation of TSCPreparing for Phase 2 stroke trial with in-ambulance administration of TSC ...
Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC
June 12, 2018 08:30 ET
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., June 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...